HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Herbalife’s China Growth Plan Includes Expediting Business Licensing, Tighter Hiring Standards

Executive Summary

Four-point China initiative also includes implementing sales strategy already a fixture in other regions, nutrition clubs with daily meetings. China's April-June results compelled firm to lower earnings forecast.

You may also be interested in...



Herbalife Reports Second Straight Year Of Record Sales And Of Costs Climbing Due To Pandemic

Herbalife’s Asia-Pacific region led 2021 sales growth even as China sales continued to slide despite initiatives to boost business there. It reported record sales levels despite limits due to COVID-19 pandemic on shopping and other consumer activity while pandemic continues impacting supply and shipping costs and influenced 2022 earnings forecast.

Herbalife Survey Points To Emphasizing Digital For Growing Asia-Pacific Sales

Survey of more than 5,000 Asia-Pacific consumers finds 56% use technology tools such as nutrition apps to support healthy living, suggesting opportunity to connect with consumers.

US Q3 Consumer Health Earnings Preview: Helm Changes, Supply Challenges, Separation Plan

July-September results for sales of OTC drugs, supplements and personal care products will come with CEO leaving J&J and P&G, a new leader for Perrigo Americas, Bausch Health likely offering Bausch + Lomb separation details and a cloud of rising costs related to supplies.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS151623

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel